- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06041217
A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range (STEP12)
April 1, 2024 updated by: Novo Nordisk A/S
Efficacy and Safety of Semaglutide 2.4 mg Once-weekly in Adults With Overweight and Obesity
This study will look at how the investigational dose of semaglutide works in helping people with excess body weight, to lose weight.
This study will compare the weight loss in people taking semaglutide to people taking "dummy" medicine (placebo).
The study will last for about 1 year.
The participants will have 12 visits at the clinic and 3 remote visits by phone calls with the study doctor or staff.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
162
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Novo Nordisk
- Phone Number: (+1) 866-867-7178
- Email: clinicaltrials@novonordisk.com
Study Locations
-
-
-
Hengshui, China, 053000
- Withdrawn
- Harrison International Peace Hospital
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Beijing Hospital
-
-
Chongqing
-
ChongQing, Chongqing, China, 404000
- Recruiting
- Chongqing University Three Gorges Hospital
-
-
Fujian
-
Fuzhou, Fujian, China, 350001
- Recruiting
- Fujian Medical University Union Hospital
-
-
Guangdong
-
Huizhou, Guangdong, China, 516001
- Recruiting
- Huizhou Central People's Hospital
-
-
Hubei
-
Shiyan, Hubei, China, 442008
- Recruiting
- Taihe Hospital
-
-
Jiangsu
-
Changzhou, Jiangsu, China, 213003
- Recruiting
- Changzhou No.2 People's Hospital, Yanghu Branch
-
Nanjing, Jiangsu, China, 210011
- Recruiting
- The Second Affiliated Hospital of Nanjing Medical University_Nanjing
-
Zhenjiang, Jiangsu, China, 212001
- Recruiting
- The Affiliated Hospital of Jiangsu University_Zhenjiang
-
-
Jilin
-
Changchun, Jilin, China, 130021
- Recruiting
- The First Hospital of Jilin University
-
-
Qinghai
-
Xining, Qinghai, China, 810007
- Recruiting
- Qinghai Provincial People's Hospital
-
-
Shandong
-
Ji'nan, Shandong, China, 250013
- Recruiting
- Jinan Central Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China, 200240
- Recruiting
- Shanghai Fifth People's Hospital
-
Shanghai, Shanghai, China, 200336
- Recruiting
- Tongren Hospital Shanghai Jiao Tong Univ. School of Medicine
-
Shanghai, Shanghai, China, 201200
- Recruiting
- Shanghai Pudong New Area People's Hospital
-
-
-
-
-
Chiayi City, Taiwan, 600
- Recruiting
- Ditmanson Medical Foundation Chia-Yi Christian Hospital
-
Taichung, Taiwan, 404
- Recruiting
- China Medical University Hospital
-
Tainan City, Taiwan, 704
- Recruiting
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 100
- Recruiting
- National Taiwan University Hospital
-
Taipei city, Taiwan, 110
- Recruiting
- Taipei Medical University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Age greater than or equal to 18 years at the time of signing informed consent.
- Body mass index (BMI) of greater than or equal to 24 and less than 28 kilogram per square meter ( kg/m^2) with the presence of at least one weight related complication (treated or untreated): Type 2 diabetes (T2D), hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease or BMI greater than or equal to 28 and less 30 kg/m^2, with or without weight related complications at screening.
- History of at least one self-reported unsuccessful dietary effort to lose body weight.
For participants with T2D at screening:
- Diagnosed with T2D greater than or equal to 180 days prior to the day of screening
Treated with either:
- Diet and exercise alone or with 1-3 marketed oral antidiabetic drugs (metformin, alpha glucosidase, Sulfonylureas (SU), glinides, sodium-glucose co-transporter 2 inhibitors (SGLT2i) or glitazone as a single agent or in combination) according to local label.
- Treatment with oral anti-diabetic drugs should be stable (same drug(s) or active ingredient, dose, and dosing frequency) for at least 60 days before screening
- Glycated haemoglobin (HbA1c) of less than or equal to 10.0 percent (less than or equal to 86 millimoles per mol [mmol/mol]) as measured by the central laboratory at screening.
Exclusion Criteria:
- A self-reported change in body weight greater than 5 kilograms (kg) within 90 days before screening irrespective of medical records.
- Treatment with any medication for the indication of obesity within the past 90 days before screening.
- Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma.
For participants without T2D at screening:
- HbA1c greater than or equal to 6.5percent (48 mmol/mol) as measured by the laboratory.
For participants with T2D at screening:
- Renal impairment with estimated Glomerular Filtration Rate (eGFR) value of less than 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m^2) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by Kidney Disease Improving Global Outcomes (KDIGO) 2012 classification by the central laboratory at screening.
- Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days prior to screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Semaglutide 2.4 milligram (mg)
Participants will receive once-weekly subcutaneous (s.c) injection of semaglutide for 44 weeks.
|
Subcutaneous injections of semaglutide once-weekly at escalating doses every fourth week until maintenance dose of 2.4 mg of semaglutide is reached.
|
Placebo Comparator: Placebo
Participants will receive once-weekly subcutaneous (s.c) injection of placebo for 44 weeks.
|
Subcutaneous injections of placebo once-weekly at escalation doses manner as semaglutide every fourth week until maintenance dose of placebo matched to 2.4 mg is reached.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Relative change in body weight
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in percentage (%).
|
From baseline (week 0) to end of treatment (week 44)
|
Body weight reduction ≥ 5% (yes/no)
Time Frame: At end of treatment (week 44)
|
Measured as count of participants.
|
At end of treatment (week 44)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Body weight reduction ≥ 10% (yes/no)
Time Frame: At end of treatment (week 44)
|
Measured as count of participants.
|
At end of treatment (week 44)
|
Change in waist circumference
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in centimeter.
|
From baseline (week 0) to end of treatment (week 44)
|
Change in body weight
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in kilograms (kg).
|
From baseline (week 0) to end of treatment (week 44)
|
Change in body mass index
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in kilograms per square meter (kg/m^2).
|
From baseline (week 0) to end of treatment (week 44)
|
Change in systolic blood pressure
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in millimeters of mercury (mmHg).
|
From baseline (week 0) to end of treatment (week 44)
|
Change in diastolic blood pressure
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in mmHg.
|
From baseline (week 0) to end of treatment (week 44)
|
Change in total cholesterol
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in ratio to baseline.
|
From baseline (week 0) to end of treatment (week 44)
|
Change in high-density lipoprotein (HDL) cholesterol
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in ratio to baseline.
|
From baseline (week 0) to end of treatment (week 44)
|
Change in low-density lipoprotein (LDL) cholesterol
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in ratio to baseline.
|
From baseline (week 0) to end of treatment (week 44)
|
Change in very low-density lipoprotein (VLDL) cholesterol
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in ratio to baseline.
|
From baseline (week 0) to end of treatment (week 44)
|
Change in triglycerides
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in ratio to baseline.
|
From baseline (week 0) to end of treatment (week 44)
|
Change in free fatty acids
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in ratio to baseline.
|
From baseline (week 0) to end of treatment (week 44)
|
Change in high-sensitivity c-reactive protein (hsCRP)
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in ratio to baseline.
|
From baseline (week 0) to end of treatment (week 44)
|
Change in Glycated Haemoglobin (HbA1c) (Percent [%])
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in percentage point.
|
From baseline (week 0) to end of treatment (week 44)
|
Change in HbA1c (mmol/mol)
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in millimoles per mole (mmol/mol).
|
From baseline (week 0) to end of treatment (week 44)
|
Change in fasting plasma glucose (mg/dL)
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in milligrams per deciliter (mg/dL).
|
From baseline (week 0) to end of treatment (week 44)
|
Change in fasting plasma glucose (mmol/L)
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in mmol/L
|
From baseline (week 0) to end of treatment (week 44)
|
Number of Treatment-emergent Adverse Events (TEAEs)
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in count of events.
|
From baseline (week 0) to end of treatment (week 44)
|
Number of Serious Adverse Events (SAEs)
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in count of events.
|
From baseline (week 0) to end of treatment (week 44)
|
Change in pulse
Time Frame: From baseline (week 0) to end of treatment (week 44)
|
Measured in beats per minute (bpm).
|
From baseline (week 0) to end of treatment (week 44)
|
Number of clinically significant hypoglycaemic episodes (level 2) (less than [<] 3.0 millimole per liter [mmol/L]) confirmed by blood glucose [BG] meter)
Time Frame: From baseline (week 0) to end of study (week 49)
|
Measured in number of episodes.
|
From baseline (week 0) to end of study (week 49)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Clinical Transparency (dept. 2834), Novo Nordisk A/S
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 15, 2023
Primary Completion (Estimated)
May 7, 2025
Study Completion (Estimated)
June 11, 2025
Study Registration Dates
First Submitted
September 11, 2023
First Submitted That Met QC Criteria
September 11, 2023
First Posted (Actual)
September 18, 2023
Study Record Updates
Last Update Posted (Actual)
April 2, 2024
Last Update Submitted That Met QC Criteria
April 1, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NN9536-4706
- U1111-1273-4538 (Other Identifier: World Health Organization (WHO))
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
According to the Novo Nordisk disclosure commitment on novonordisktrials.com
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
Central Hospital, Nancy, FranceNot yet recruiting
-
University of MinnesotaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Active, not recruitingAdolescent ObesityUnited States
-
Helsinki University Central HospitalKarolinska Institutet; Folkhälsan Researech CenterEnrolling by invitation
-
Istanbul Medipol University HospitalMedipol UniversityCompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, VisceralTurkey
-
Queen Fabiola Children's University HospitalNot yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric SurgeryBelgium
-
Azienda Ospedaliero-Universitaria Consorziale Policlinico...Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies; Istituti... and other collaboratorsCompletedMorbid Obesity | Metabolically Healthy ObesityItaly
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; Pennington Biomedical Research... and other collaboratorsActive, not recruitingOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood | Overweight and Obesity | Overweight or Obesity | Overweight AdolescentsUnited States
-
The Hospital for Sick ChildrenCompleted
-
Ihuoma EneliCompletedObesity, ChildhoodUnited States
-
Fundació Sant Joan de DéuRecruitingObesity, Childhood | Obesity, AdolescentSpain
Clinical Trials on Semaglutide
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, India, Japan, Russian Federation, United Kingdom, Canada, Spain, South Africa, Germany, Greece, United Arab Emirates, Argentina, Puerto Rico
-
Novo Nordisk A/SCompletedObesityUnited States, Israel, United Kingdom, Denmark, Germany, Netherlands, Canada, Argentina, Czechia, Hungary, Poland, Spain, Australia
-
Novo Nordisk A/SCompletedObesity | Diabetes Mellitus, Type 2 | OverweightKorea, Republic of, Hong Kong, Brazil, China
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States
-
Novo Nordisk A/SCompletedDiabetes Mellitus, Type 2Germany
-
Novo Nordisk A/SCompletedType 2 Diabetes | Healthy VolunteersUnited States, Canada
-
Sansum Diabetes Research InstituteNovo Nordisk A/STerminatedDiabetes Mellitus, Type 2 | Glucose Metabolism Disorders (Including Diabetes Mellitus)United States
-
Novo Nordisk A/SCompletedObesity | OverweightUnited States, Italy, Spain, Canada, Hungary
-
Novo Nordisk A/SCompletedObesity | OverweightJapan, Korea, Republic of
-
Novo Nordisk A/SCompletedOverweight or Obesity | Metabolism and Nutrition DisorderUnited States, India, Mexico, Russian Federation, United Kingdom, Canada, Denmark, Finland, Belgium, Japan, Taiwan, France, Poland, Germany, Bulgaria, Argentina, Puerto Rico